Literature DB >> 12496074

Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity.

M Germana Paterlini1.   

Abstract

The G-protein coupled receptor CCR5 is the main co-receptor for macrophage-tropic HIV-1 strains. I have built a structural model of the chemokine receptor CCR5 and used it to explain the binding and selectivity of the antagonist TAK779. Models of the extracellular (EC) domains of CCR5 have been constructed and used to rationalize current biological data on the binding of HIV-1 and chemokines. Residues spanning the transmembrane region of CCR5 have been modeled after rhodopsin, and their functional significance examined using the evolutionary trace method. The receptor cavity shares six residues with CC-chemokine receptors CCR1 through CCR4, while seven residues are unique to CCR5. The contribution of these residues to ligand binding and selectivity is tested by molecular docking simulations of TAK779 to CCR1, CCR2, and CCR5. TAK779 binds to CCR5 in the cavity formed by helices 1, 2, 3, and 7 with additional interactions with helices 5 and 6. TAK779 did not dock to either CCR1 or CCR2. The results are consistent with current site-directed mutagenesis data and with the observed selectivity of TAK779 for CCR5 over CCR1 and CCR2. The specific residues responsible for the observed selectivity are identified. The four EC regions of CCR5 have been modeled using constrained simulated annealing simulations. Applied dihedral angle constraints are representative of the secondary structure propensities of these regions. Tertiary interactions, in the form of distance constraints, are generated from available epitope mapping data. Analysis of the 250 simulated structures provides new insights to the design of experiments aimed at determining residue-residue contacts across the EC domains and for mapping CC-chemokines on the surface of the EC domains.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12496074      PMCID: PMC1302382          DOI: 10.1016/S0006-3495(02)75307-1

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  82 in total

1.  Comparative protein modelling by satisfaction of spatial restraints.

Authors:  A Sali; T L Blundell
Journal:  J Mol Biol       Date:  1993-12-05       Impact factor: 5.469

2.  Fingerprinting G-protein-coupled receptors.

Authors:  T K Attwood; J B Findlay
Journal:  Protein Eng       Date:  1994-02

3.  An evolutionary trace method defines binding surfaces common to protein families.

Authors:  O Lichtarge; H R Bourne; F E Cohen
Journal:  J Mol Biol       Date:  1996-03-29       Impact factor: 5.469

4.  Volume changes on protein folding.

Authors:  Y Harpaz; M Gerstein; C Chothia
Journal:  Structure       Date:  1994-07-15       Impact factor: 5.006

5.  The prediction and orientation of alpha-helices from sequence alignments: the combined use of environment-dependent substitution tables, Fourier transform methods and helix capping rules.

Authors:  D Donnelly; J P Overington; T L Blundell
Journal:  Protein Eng       Date:  1994-05

Review 6.  Structure and function of G protein-coupled receptors.

Authors:  C D Strader; T M Fong; M R Tota; D Underwood; R A Dixon
Journal:  Annu Rev Biochem       Date:  1994       Impact factor: 23.643

7.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.

Authors:  J D Thompson; D G Higgins; T J Gibson
Journal:  Nucleic Acids Res       Date:  1994-11-11       Impact factor: 16.971

8.  -mu opiate receptor. Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity.

Authors:  C K Surratt; P S Johnson; A Moriwaki; B K Seidleck; C J Blaschak; J B Wang; G R Uhl
Journal:  J Biol Chem       Date:  1994-08-12       Impact factor: 5.157

9.  Arrangement of transmembrane domains in adrenergic receptors. Similarity to bacteriorhodopsin.

Authors:  T Mizobe; M Maze; V Lam; S Suryanarayana; B K Kobilka
Journal:  J Biol Chem       Date:  1996-02-02       Impact factor: 5.157

10.  A reciprocal mutation supports helix 2 and helix 7 proximity in the gonadotropin-releasing hormone receptor.

Authors:  W Zhou; C Flanagan; J A Ballesteros; K Konvicka; J S Davidson; H Weinstein; R P Millar; S C Sealfon
Journal:  Mol Pharmacol       Date:  1994-02       Impact factor: 4.436

View more
  22 in total

1.  G protein-coupled receptors: in silico drug discovery in 3D.

Authors:  Oren M Becker; Yael Marantz; Sharon Shacham; Boaz Inbal; Alexander Heifetz; Ori Kalid; Shay Bar-Haim; Dora Warshaviak; Merav Fichman; Silvia Noiman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-26       Impact factor: 11.205

2.  CCR5 interactions with the variable 3 loop of gp120.

Authors:  Kelby B Napier; Zi-xuan Wang; Stephen C Peiper; John O Trent
Journal:  J Mol Model       Date:  2006-05-24       Impact factor: 1.810

3.  Chemokine CCR5 and cocaine interactions in the brain: Cocaine enhances mesolimbic CCR5 mRNA levels and produces place preference and locomotor activation that are reduced by a CCR5 antagonist.

Authors:  Sunil U Nayak; Stephanie Cicalese; Chris Tallarida; Chicora F Oliver; Scott M Rawls
Journal:  Brain Behav Immun       Date:  2019-09-23       Impact factor: 7.217

4.  Estimation of 2Nes from temporal allele frequency data.

Authors:  Jonathan P Bollback; Thomas L York; Rasmus Nielsen
Journal:  Genetics       Date:  2008-05       Impact factor: 4.562

Review 5.  In silico studies on DARC.

Authors:  Alexandre G de Brevern; Ludovic Autin; Yves Colin; Olivier Bertrand; Catherine Etchebest
Journal:  Infect Disord Drug Targets       Date:  2009-06

6.  Impact of chemokines CCR5∆32, CXCL12G801A, and CXCR2C1208T on bladder cancer susceptibility in north Indian population.

Authors:  Vibha Singh; Praveen Kumar Jaiswal; Rohit Kapoor; Rakesh Kapoor; Rama Devi Mittal
Journal:  Tumour Biol       Date:  2014-01-16

7.  Adaptive Gene Loss? Tracing Back the Pseudogenization of the Rabbit CCL8 Chemokine.

Authors:  Wessel van der Loo; Maria João Magalhaes; Ana Lemos de Matos; Joana Abrantes; Fumio Yamada; Pedro J Esteves
Journal:  J Mol Evol       Date:  2016-06-15       Impact factor: 2.395

8.  Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.

Authors:  Patrick Dorr; Mike Westby; Susan Dobbs; Paul Griffin; Becky Irvine; Malcolm Macartney; Julie Mori; Graham Rickett; Caroline Smith-Burchnell; Carolyn Napier; Rob Webster; Duncan Armour; David Price; Blanda Stammen; Anthony Wood; Manos Perros
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

9.  Analysis of binding sites for the new small-molecule CCR5 antagonist TAK-220 on human CCR5.

Authors:  Masao Nishikawa; Katsunori Takashima; Toshiya Nishi; Rika A Furuta; Naoyuki Kanzaki; Yoshio Yamamoto; Jun-Ichi Fujisawa
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

10.  Toward the discovery of vaccine adjuvants: coupling in silico screening and in vitro analysis of antagonist binding to human and mouse CCR4 receptors.

Authors:  Matthew N Davies; Jagadeesh Bayry; Elma Z Tchilian; Janakiraman Vani; Melkote S Shaila; Emily K Forbes; Simon J Draper; Peter C L Beverley; David F Tough; Darren R Flower
Journal:  PLoS One       Date:  2009-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.